Journal article

Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer

Wolfgang P Fendler, Manuel Weber, Amir Iravani, Michael S Hofman, Jeremie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Eric J Small, Matthew R Smith, Paola M Perez, Thomas A Hope, Isabel Rauscher, Anil Londhe, Angela Lopez-Gitlitz, Shinta Cheng, Tobias Maurer, Ken Herrmann, Matthias Eiber, Boris Hadaschik

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2019

Abstract

PURPOSE: Systemic androgen-signaling inhibition added to ongoing androgen-deprivation therapy (ADT) improved clinical outcomes in patients with nonmetastatic castration-resistant prostate cancer without detectable metastases by conventional imaging (nmCRPC). Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) detects prostate cancer with superior sensitivity to conventional imaging, but its performance in nmCRPC remains largely unknown. We characterized cancer burden in high-risk patients with nmCRPC using PSMA-PET. EXPERIMENTAL DESIGN: We retrospectively included 200 patients with nmCRPC, prostate-specific antigen (PSA) >2 ng/mL, and high risk for metastatic di..

View full abstract

Grants

Awarded by German Research Foundation


Awarded by Mercator Research Center Ruhr (MERCUR)


Awarded by IFORES


Funding Acknowledgements

The authors thank Bernhard Haller, MD, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany, for his assistance in conducting the multivariable analyses, and Axel Wetter, MD, University of Duisburg-Essen, Department of Radiology, for help with database analyses. PSMA-PET data acquisition and analyses were conducted as part of an investigator-initiated study headed by the University of Duisburg-Essen, Department of Nuclear Medicine. W.P. Fendler received financial support from the German Research Foundation (FE1573/1-1/807122 and FE1573/3-1/659216), Mercator Research Center Ruhr (MERCUR, An-2019-0001), IFORES (D/107-81260 and D/107-30240), Doktor Robert Pfleger-Stiftung, and Wiedenfeld-Stiftung/Stiftung Krebsforschung Duisburg. Participating centers for the PSMA-PET study provided institutional support for ethics review, database creation, data entry, and central reading of PET data. Contribution of SPARTAN data was funded by Janssen Global Services. Writing assistance was provided by Larissa Belova, PhD, and Ira Mills, PhD, of PAREXEL and was funded by Janssen Global Services, LLC.